866-997-4948(US-Canada Toll Free)

Hepatocellular Carcinoma - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 960 Pages

Hepatocellular Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 16, 69, 42, 4, 62 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 4, 1, 21 and 2 molecules, respectively.Hepatocellular Carcinoma.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Hepatocellular Carcinoma Overview 9
Therapeutics Development 10
Hepatocellular Carcinoma - Therapeutics under Development by Companies 12
Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 22
Hepatocellular Carcinoma - Pipeline Products Glance 24
Hepatocellular Carcinoma - Products under Development by Companies 27
Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 42
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 44
Hepatocellular Carcinoma - Therapeutics Assessment 178
Drug Profiles 206
Hepatocellular Carcinoma - Dormant Projects 900
Hepatocellular Carcinoma - Discontinued Products 911
Hepatocellular Carcinoma - Product Development Milestones 915
Appendix 933

List of Tables
Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016 37
Number of Products under Development by Companies, H2 2016 38
Number of Products under Development by Companies, H2 2016 (Contd..1) 39
Number of Products under Development by Companies, H2 2016 (Contd..2) 40
Number of Products under Development by Companies, H2 2016 (Contd..3) 41
Number of Products under Development by Companies, H2 2016 (Contd..4) 42
Number of Products under Development by Companies, H2 2016 (Contd..5) 43
Number of Products under Development by Companies, H2 2016 (Contd..6) 44
Number of Products under Development by Companies, H2 2016 (Contd..7) 45
Number of Products under Development by Companies, H2 2016 (Contd..8) 46
Number of Products under Development by Companies, H2 2016 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H2 2016 48
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49
Comparative Analysis by Late Stage Development, H2 2016 50
Comparative Analysis by Clinical Stage Development, H2 2016 51
Comparative Analysis by Early Stage Development, H2 2016 52
Products under Development by Companies, H2 2016 53
Products under Development by Companies, H2 2016 (Contd..1) 54
Products under Development by Companies, H2 2016 (Contd..2) 55
Products under Development by Companies, H2 2016 (Contd..3) 56
Products under Development by Companies, H2 2016 (Contd..4) 57
Products under Development by Companies, H2 2016 (Contd..5) 58
Products under Development by Companies, H2 2016 (Contd..6) 59
Products under Development by Companies, H2 2016 (Contd..7) 60
Products under Development by Companies, H2 2016 (Contd..8) 61
Products under Development by Companies, H2 2016 (Contd..9) 62
Products under Development by Companies, H2 2016 (Contd..10) 63
Products under Development by Companies, H2 2016 (Contd..11) 64
Products under Development by Companies, H2 2016 (Contd..12) 65
Products under Development by Companies, H2 2016 (Contd..13) 66
Products under Development by Companies, H2 2016 (Contd..14) 67
Products under Investigation by Universities/Institutes, H2 2016 68
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69
Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2016 70
Hepatocellular Carcinoma - Pipeline by AB Science SA, H2 2016 71
Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H2 2016 72
Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H2 2016 73
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 74
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2016 75
Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2016 76
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2016 77
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2016 78
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2016 79
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2016 80
Hepatocellular Carcinoma - Pipeline by Astellas Pharma Inc, H2 2016 81
Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 82
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2016 83
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 84
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2016 85
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2016 86
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 87
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2016 88
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2016 89
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 90
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2016 91
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 92
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016 93
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2016 94
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2016 95
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2016 96
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2016 97
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2016 98
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2016 99
Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd, H2 2016 100
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 101
Hepatocellular Carcinoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 102
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2016 103
Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 104
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 105
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2016 106
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 107
Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H2 2016 108
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2016 109
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016 110
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2016 111
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 112
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2016 113
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2016 114
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2016 115
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2016 116
Hepatocellular Carcinoma - Pipeline by Genosco, H2 2016 117
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2016 118
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016 119
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2016 120
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2016 121
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2016 122
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2016 123
Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H2 2016 124
Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H2 2016 125
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016 126
Hepatocellular Carcinoma - Pipeline by Immune Therapeutics, Inc., H2 2016 127
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2016 128
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2016 129
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2016 130
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2016 131
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2016 132
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 133
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016 134
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2016 135
Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H2 2016 136
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2016 137
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2016 138
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2016 139
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2016 140
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2016 141
Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H2 2016 142
Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H2 2016 143
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 144
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 145
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2016 146
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2016 147
Hepatocellular Carcinoma - Pipeline by Medivation Inc, H2 2016 148
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2016 149
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2016 150
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2016 151
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 152
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2016 153
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 154
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2016 155
Hepatocellular Carcinoma - Pipeline by Molecular Partners AG, H2 2016 156
Hepatocellular Carcinoma - Pipeline by MolMed SpA, H2 2016 157
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2016 158
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2016 159
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2016 160
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2016 161
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2016 162
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2016 163
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2016 164
Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 165
Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H2 2016 166
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2016 167
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 168
Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2016 169
Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H2 2016 170
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 171
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2016 172
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2016 173
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2016 174
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2016 175
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2016 176
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2016 177
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 178
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2016 179
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2016 180
Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2016 181
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2016 182
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2016 183
Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 184
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016 185
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016 186
Hepatocellular Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 187
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2016 188
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 189
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2016 190
Hepatocellular Carcinoma - Pipeline by Theravectys SA, H2 2016 191
Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 192
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016 193
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 194
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2016 195
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2016 196
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2016 197
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2016 198
Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H2 2016 199
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2016 200
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2016 201
Hepatocellular Carcinoma - Pipeline by Virttu Biologics Ltd, H2 2016 202
Hepatocellular Carcinoma - Pipeline by Vyriad Inc, H2 2016 203
Assessment by Monotherapy Products, H2 2016 204
Assessment by Combination Products, H2 2016 205
Number of Products by Stage and Target, H2 2016 207
Number of Products by Stage and Mechanism of Action, H2 2016 218
Number of Products by Stage and Route of Administration, H2 2016 229
Number of Products by Stage and Molecule Type, H2 2016 231
Hepatocellular Carcinoma - Dormant Projects, H2 2016 926
Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2016 927
Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2016 928
Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2016 929
Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2016 930
Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2016 931
Hepatocellular Carcinoma - Dormant Projects (Contd..6), H2 2016 932
Hepatocellular Carcinoma - Dormant Projects (Contd..7), H2 2016 933
Hepatocellular Carcinoma - Dormant Projects (Contd..8), H2 2016 934
Hepatocellular Carcinoma - Dormant Projects (Contd..9), H2 2016 935
Hepatocellular Carcinoma - Dormant Projects (Contd..10), H2 2016 936
Hepatocellular Carcinoma - Discontinued Products, H2 2016 937
Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2016 938
Hepatocellular Carcinoma - Discontinued Products (Contd..2), H2 2016 939
Hepatocellular Carcinoma - Discontinued Products (Contd..3), H2 2016 940

List of Figures
Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36
Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016 37
Number of Products under Development by Companies, H2 2016 38
Number of Products under Investigation by Universities/Institutes, H2 2016 48
Comparative Analysis by Late Stage Development, H2 2016 50
Comparative Analysis by Clinical Stage Development, H2 2016 51
Comparative Analysis by Early Stage Products, H2 2016 52
Assessment by Monotherapy Products, H2 2016 204
Assessment by Combination Products, H2 2016 205
Number of Products by Top 10 Targets, H2 2016 206
Number of Products by Stage and Top 10 Targets, H2 2016 206
Number of Products by Top 10 Mechanism of Actions, H2 2016 217
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 217
Number of Products by Top 10 Routes of Administration, H2 2016 228
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228
Number of Products by Top 10 Molecule Types, H2 2016 230
Number of Products by Stage and Top 10 Molecule Types, H2 2016 230

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *